Levemir Articles
EU OKs two new indications for Novo Nordisk’s Levemir
3 November 2011
Approval of diabetes drugs from AstraZeneca/B-MS and Novo Nordisk supported by EU’s CHMP; Faslodex cleared in Japan
26 September 2011
Biosimilar insulins and analogs set to erode $6.1 billion in brand sales in the USA and Europe by 2018
15 October 2009
Novo Nordisk initiates new Levemir study
5 June 2009
Novo Nordisk's Levemir lowers ave blood sugar
14 May 2009
Novo to invest $400M in China insulin plant
17 November 2008
Levemir comparable to glargine in control and DACON
16 June 2008
More NCEs added to Japan's NHI reimbursement list late December
14 January 2008
Japan's MHLW clears Novo Nordisk's Levemir
29 October 2007
No weight gain for "majority" on Levemir
16 April 2007
Levemir demonstrates safety and efficacy
7 February 2007
Encouraging weight loss findings for Levemir
18 December 2006
Novo Nordisk boosts US sales force
11 December 2006
Unique benefits with Levemir and NovoRapid
25 September 2006
19 additions to Italy's reimbursement list
20 February 2006
Novo Nordisk sees a 16% climb in profits
6 February 2006
Insulin detemir limits diabetic weight gain
19 September 2005
Novo's Levemir Ok'd in USA for diabetes
27 June 2005
FDA approves Levemir
27 June 2005
US volume Rx sales rise 8.3% in 2004
21 February 2005
Novo Nordisk sees 4% profits rise for 2004
14 February 2005
New product launches in 2004
31 January 2005
Novo Nordisk's Levemir available in UK
28 June 2004
EU clears Novo Nordisk's Levemir
14 June 2004
Novo Nordisk's Levemir on track in EU
8 March 2004
Novo Nordisk profits up 19% in 2003
16 February 2004
Approvable letter for Levemir from FDA
20 October 2003
Novo Nordisk
8 September 2003
Showing 1-40 of 40 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
